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Summary In 101 breast cancer patients, measurement of oestrogen receptor status in multiple biopsies across
a tumour reveals a highly significant difference in the proportion of patients remaining either disease-free
(P<0.04) or alive (P<0.005), when those with uniformly receptor positive (+ +) primary tumours are matched
with clinically comparable patients whose tumours were homogeneously receptor negative (- -). Mean
follow-up time was 85 months. The prognostic value of this discriminant is particularly striking in the 53
patients with involved nodes at presentation. Of these, 13 were (+ +) and seven remain alive of whom six are
disease-free, whereas 24 of the 29 (- -) patients are dead. These results further suggest that receptor assay
on a single homogenate gives less clinical information than do assays on multiple biopsies across the tumour.
For patients with involved nodes, clinical management may best be decided after determination of
'macroheterogeneity'.
Breast cancer patients who have involved nodes at initial
presentation are known to have a relatively poor prognosis.
Nevertheless, some node-involved patients survive much
longer than others who appear to have clinically comparable
disease (Blamey et al., 1980). Some prognostic information
can be obtained by measuring oestrogen receptor (ER) status
in a single biopsy of the primary tumour. For example, it
has been shown (Croton et al., 1977) that soluble oestrogen
receptor can distinguish good and bad prognosis groups
within node-negative (No) and, particularly (Williams et al.,
1987; Report from the Breast Cancer Trials Committee,
1987), node-positive disease. Unfortunately, soluble oestro-
gen receptor status gives no information about disease-free
interval, being simply an index of survival time from relapse
to death (Mason et al., 1983; Howell et al., 1984; Howat et
al., 1985). Better prognostic information can be obtained by
measuring either the combination of soluble oestrogen and
progesterone receptors (Wittliff, 1984), or both soluble and
nuclear oestrogen receptor content (Leake et al., 1979,
1981b) in a single biopsy of primary disease.
As a reflection of the biological heterogeneity of human
cancers, including breast, oestrogen receptor content is
known to vary across tumours either quantitatively or
qualitatively, whether expressed relative to protein or DNA
content (Silverswaard et al., 1980; Strauss et al., 1982;
Raemakers et al., 1984; Pertschuk et al., 1985; Castagnetta et
al., 1985, 1987b). In an attempt to further identify the good
and bad prognosis patients within any clinical subgroup, we
have taken, from a necessarily limited number of patients,
multiple biopsies across primary tumours and measured both
soluble and nuclear oestrogen receptor content in each.
These assays were carried out on tissue homogenates and the
macroheterogeneity observed (defined by the hormone sensi-
tivity or HS status, see Methods) should not be confused
with the microheterogeneity revealed by immunocyto-
chemical staining (Charpin et al., 1986). This paper reports
data on the prognostic value (in terms of both disease-free
interval and total survival) of HS status in breast cancer, in
relation to tumour size, nodal involvement and menopausal
status.
Patients and methods
A group of 101 breast cancer patients with no overt signs of
distant metastases, all attended the 'M. Ascoli' Cancer
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Hospital Centre in Palermo and underwent radical (Halstead
or Patey modified) mastectomy. A minimum of 10 nodes
were removed from each patient for subsequent pathological
examination. Patients were followed up at regular intervals
(every 3 months for the first 2 years, every 6 months
thereafter) for at least 64 months (mean 85.1 + 11.2 months,
range 64-106 months).
At presentation, 57 patients were stage 3 or 4 and 53 had
involved nodes. Each tumour was halved and one half used
for pathological classification. The other half was cut into at
least three (up to five) sections. Each was assessed for
oestrogen receptor content in both the nuclear and soluble
fractions using our standard competition assay (Castagneta
et al., 1983; Leake & Habib, 1987). The ligand range (10-10
to 10 9M) and dissociation constant cut-off (5.5 x I0-10M)
ensured that receptor was purely type 1 (confirmed, where
possible, using size-exclusion HPLC). The section adjacent to
all samples assayed was checked for adequate cellularity
determined both microscopically and on the basis of total
DNA content.
HS status, as used in this study, is defined as follows:
patients whose primary tumours showed a positive oestrogen
receptor status (ER+) in all three (central, intermediate and
peripheral) sections assayed were designated (+ +). ER+
indicates that the receptor content of both the soluble and
nuclear fractions exceeded 240fmolmg-1 DNA (see
Castagnetta et al., 1983; Leake et al., 1981a); this cut-off
value is roughly equivalent to 12fmolmg-1 cytosol protein
for the soluble fraction. Patients whose tumours contained
less than the cut-off value of soluble and/or nuclear recep-
tors in any section, but contained adequate amounts else-
where were (+-) and those whose tumours were below the
cut-off in all sections were (- -). Previous experience has
shown that the best clinical discrimination of hormone
sensitive from resistant tumours is achieved by measuring
both soluble and nuclear receptor concentration, then
expressing the results per unit DNA (Castagnetta et al.,
1983, 1987a).
Patient treatment
After surgery, 85% of (+ +) and 89% of (--) patients
with involved nodes (both pre- and post-menopausal)
received CMF (12 courses). Pre-menopausal, node-negative
patients received no further treatment. Of the post-meno-
pausal node-negative patients, 33% of (+ +) and 40% of
(- -) received simple postoperative radiotherapy. The
remainder received no further treatment. Patients with (+ -)
disease were treated as (- -). Tumours were classified
according to the TNM staging handbook (UICC, 1982).
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Table I Clinical features of patients/tumours in relation to HS status
Post-menopausal Post-menopausal Involved
HS status Pre-menopausal <10 years >10 years No nodes nodes
(+ +) n=36 8 13 15 23 13
(+-) n= 15 4 4 7 4 11
(--) n=50 22 15 13 21 29
Total 101 34 32 35 48 53
Results
The HS status subgroups were related to the clinical features
of disease as shown in Table I. Overall, 57% of tumours
could have been classified as ER positive if only a single
soluble fraction had been measured for ER content. After
assessment of ER status in at least three biopsies across the
primaries, only 36% of patients had tumours which were HS
(+ +) (only 24% of tumours from pre-menopausal patients
were (+ +)).
As shown in Table I, a large proportion of these patients
showed clinical features associated with poor prognosis
(nodal involvement and/or pre-menopausal status (see
Koscielny et al., 1984; Kaplan et al., 1985; Padmanabhan et
al., 1986)). In addition, out of the 53 node-positive patients,
41 (77%) were already T3-4; of the 34 pre-menopausal
patients, 22 had involved nodes. Follow-up times for the
three HS groups were strictly comparable (82.4±8.7 months
for (++); 90+9.9 for (+-) and 84.2+12.3 for (--).
Overall, of the 50 (- -) patients, 33 have died, whereas
only 12 out of 36 (+ +) patients have died. After statistical
comparison of the subgroups having different (HS) status, a
highly significant difference between (+ +) and (- -) patients
is observed in terms of both death (P<0.005) and relapse
(P<0.04, x2 tests). The follow-up of patients is shown in
Table II and the statistical comparisons are shown in Table
III.
At present, after a mean follow-up of 85.1 +11.2 months,
48 out of the 101 patients are still alive with 44 remaining
free from disease. Of these 44, 19 were in the > 10 year post-
menopausal group. Since 15 out of 35 in this older group
were HS (+ +) at presentation and 13 of the 15 were node-
negative, it might be argued that the prognostic advantage
was only attributable to nodal status. We therefore examined
survival data for the N+ patients according to the HS status
of their tumours. The results are shown in Table IV.
Within this node-involved group, the proportion of deaths
for patients with (- -) disease (24/29) is significantly
(P<0.04) greater than in the (+ +) group. Correspondingly,
in the T3-4 subgroup, 22/28 (- -) patients have died,
whereas only 8/18 (+ +) patients have died - of the 10 (+ +)
patients remaining alive, nine are disease-free. In the pre-
menopausal group, 19 patients have died. Of these, 14 were
(--) and four (+ -). Of the eight patients with (+ +)
disease, seven remain alive and six disease-free despite the
fact that four of these patients presented with T3-4 disease
and five had involved nodes.
Discussion
Breast cancers are often highly heterogeneous in terms of cell
content. For this reason, steroid receptor content can differ
both qualitatively and quantitatively across some tumours.
However, by taking multiple biopsies and assaying speci-
fically for type I receptors (high affinity receptors with
defined physical properties - confirmed by HPLC analysis,
data unpublished) and confirming the cellularity of each
section, we have been able to classify this macro-hetero-
geneity such that we can discriminate uniformly positive
tumours from both those with heterogeneous receptor distri-
bution and those which are uniformly negative (Castagnetta
et al., 1983, 1985). Because of our exacting definition of
Table II Clinical progress of patients in rela-
tion to HS status
HS status D R
(++) n=36 12a 15
(+ n)=n15 8 9
(--) n=50 33b 33
aTwo patients died of non cancer-related
causes; bOne patient died of non cancer-related
cause; D =dead; R =relapsed.
Table III Statistical comparisons of HS subgroups
in relations to relapse and death
Relapse Death
(+ +) vs. (+-) n.s. n.s.
n=36 n= 15 (P 0.4) (P-0.3)
(+ -) vs. (- -) n.s. n.s.
n= 15 n=50 (P 0.9) (P 0.6)
(+ +) vs. (--) P<0.005 P<0.04
n=36 n=50
n.s. =not significant.
Table IV Disease-free and total survival of N+ patients (n =53) in
relation to HS status
(+±+) (+-) (--)
HS status (n=13) (n=11) (n=29)
Disease-free 6 3 5
(n=13)
Alive 7 4 5
(n = 16)
Dead 6 7 24
(n =37)
receptor positivity, the incidence of ER+ is lower than that
reported by others (Hawkins et al., 1980; Silverswaard et al.,
1980; Raemaekers et al., 1984, 1987).
After analysis of the sub-groups according to their HS
status, there is a highly significant difference in the pro-
portion of patients remaining either disease-free or alive
(P<0.04 and P<0.005 respectively, using x2 tests) between
equivalent groups of patients depending on whether the HS
status of their disease at presentation was (+ +) or (- -).
The follow-up times for the HS groups were strictly com-
parable.
In all, 48 out of 101 patients are still alive and 44 of these
remain disease-free. All 33 (- -) patients who have relapsed
have also died, suggesting a relatively short relapse to death
interval for this group. Previous studies have also shown a
shorter relapse to death period for patients with ER negative
tumours (Croton et al., 1977; Howell et al., 1984). However,
the ability of HS status to predict appears to be much
stronger than that of a single measurement of soluble
oestrogen receptor status.
Of the 53 patients who have died, 37 (70%) had involved
nodes at presentation. However, not all the N+ patients have
done badly. Of the 13 N+ whose tumours were (± +), seven
remain alive and six disease free. Thus, even in a group
recognised to be of generally poor prognosis, a good progno-638 L. CASTAGNETTA et al.
sis subgroup can be biochemically characterised. Deter-
mination of HS status is, therefore, a useful method for
separating good and bad prognosis patients within the node-
involved group. This was equally true within the pre-meno-
pausal and large tumour groups. For example, within the
pre-menopausal group, mean total survival time of the
patients with (+ +) tumours is, to date, 83.6+8.2 months (in
fact, none of these patients has yet died), whereas for the
(- -) group it is 53.0+29.0 months (to date 14 patients in
this sub-group have died). For the four pre-menopausal
patients whose tumours were (+ -), mean total time is
39.0+ 15.2 months. Thus, the (+ -) cases may have a poorer
prognosis relative to the (+ +) subgroup, although this is not
yet significant. Management of patients who have clinically
poor prognosis but are (+ +) should, perhaps, be different
from those who have both clinically and biochemically poor
prognosis.
Monoclonal antibody kits for ER assay have eased the
determination of receptor status (Leclerq et al., 1986; Thorpe
et al., 1986). It is most important to demonstrate that the
monoclonal kits yield the same prognostic discrimination
obtained with the biochemical method.
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